-
Streetinsider.com's Hot Lunchtime Reads 10/13: (TWTR) (ESPR) (SSYS) (APTO)
-
Roth Capital Affirms Aptose Biosciences (APTO) at 'Buy'; Clinical Hold Update Disappointing, But Positives Remain
-
Roth Capital Upgrades Aptose Biosciences (APTO) to Buy
-
Roth Capital Downgrades Aptose Biosciences (APTO) to Neutral
-
APTO-253 Remains in Focus for Aptose Biosciences (APTO); Roth Affirms at 'Buy'

